Zobrazeno 1 - 10
of 41
pro vyhledávání: '"Masayuki Shirasawa"'
Autor:
Yasuhiko Haga, Yoshitaka Sakamoto, Keiko Kajiya, Hitomi Kawai, Miho Oka, Noriko Motoi, Masayuki Shirasawa, Masaya Yotsukura, Shun-Ichi Watanabe, Miyuki Arai, Junko Zenkoh, Kouya Shiraishi, Masahide Seki, Akinori Kanai, Yuichi Shiraishi, Yasushi Yatabe, Daisuke Matsubara, Yutaka Suzuki, Masayuki Noguchi, Takashi Kohno, Ayako Suzuki
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-19 (2023)
Abstract The mechanism underlying the development of tumors, particularly at early stages, still remains mostly elusive. Here, we report whole-genome long and short read sequencing analysis of 76 lung cancers, focusing on very early-stage lung adenoc
Externí odkaz:
https://doaj.org/article/04dd43d62a6b41fea8001fa49282ad6a
Autor:
Chie Morita, Tatsuya Yoshida, Masayuki Shirasawa, Ken Masuda, Yuji Matsumoto, Yuki Shinno, Shigehiro Yagishita, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Noriko Motoi, Yasushi Yatabe, Yuichiro Ohe
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021)
Abstract Epidermal growth factor receptor (EGFR) exon 20 insertion mutations (Exon20ins) account for 4–12% of all EGFR mutations in non-small cell lung cancer (NSCLC) patients. Data on the differences in clinical characteristics between patients wi
Externí odkaz:
https://doaj.org/article/3e86b2e7f167471e865402ee946d66a0
Autor:
Masayuki Shirasawa, Tomoya Fukui, Seiichiro Kusuhara, Yasuhiro Hiyoshi, Yoshiro Nakahara, Noriko Nishinarita, Satoshi Igawa, Katsuhiko Naoki
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-7 (2019)
Abstract Background Small cell lung cancer (SCLC) is characterized by a high propensity for metastases and a poor prognosis irrespective of high sensitivity for initial chemotherapy. Although interstitial pneumonia (IP) is one of risk factors for lun
Externí odkaz:
https://doaj.org/article/1783a8036d7b4874b38ed9119406a6d5
Autor:
Masayuki Shirasawa, Tomoya Fukui, Seiichiro Kusuhara, Shinya Harada, Noriko Nishinarita, Yasuhiro Hiyoshi, Mikiko Ishihara, Masashi Kasajima, Satoshi Igawa, Masanori Yokoba, Hisashi Mitsufuji, Masaru Kubota, Masato Katagiri, Jiichiro Sasaki, Katsuhiko Naoki
Publikováno v:
PLoS ONE, Vol 14, Iss 4, p e0214599 (2019)
PurposeOligometastasis is a state in which cancer patients have a limited number of metastatic tumors; patients with oligometastases survive longer than those with polymetastases. Extensive disease (ED)-small cell lung cancer (SCLC) is considered a s
Externí odkaz:
https://doaj.org/article/be51c472326c4b90883713aafed57ec3
Autor:
Masahiro Higashiyama, Noriko Motoi, Masaya Yotsukura, Yukihiro Yoshida, Kazuo Nakagawa, Shigehiro Yagishita, Masayuki Shirasawa, Tatsuya Yoshida, Kouya Shiraishi, Takashi Kohno, Yuichiro Ohe, Shun-ichi Watanabe
Publikováno v:
Pathology International. 73:188-197
Ciliated muconodular papillary tumor/bronchiolar adenoma (CMPT/BA) is a benign tumor with a high frequency of BRAF or EGFR mutations. It remains unclear whether CMPT/BA is associated with a specific type of lung cancer. Thus, we studied the clinicopa
Autor:
Ryoko Inaba Higashiyama, Tatsuya Yoshida, Shigehiro Yagishita, Mayu Ohuchi, Naomi Sakiyama, Masahiro Torasawa, Masayuki Shirasawa, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Akinobu Hamada, Yuichiro Ohe
Publikováno v:
Journal of Thoracic Oncology. 17:1227-1232
Administration of 400 mg pembrolizumab every 6 weeks (400 mg Q6W) has been approved on the basis of the results of simulated pharmacokinetic modeling and exposure-response analyses. Nevertheless, the safety of switching dosage from 200 mg every 3 wee
Autor:
Yukiko Shimoda, Ryota Shibaki, Tatsuya Yoshida, Shuji Murakami, Masayuki Shirasawa, Masahiro Torasawa, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe, Noriko Motoi
Publikováno v:
Clinical Lung Cancer. 23:477-486
Autor:
Ryoko Inaba Higashiyama, Tatsuya Yoshida, Masayuki Shirasawa, Sayaka Arakawa, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Publikováno v:
Haigan. 61:939-945
Autor:
Yuichiro Ohe, Tatsuya Yoshida, Noboru Yamamoto, Takashi Kubo, Noriko Motoi, Yuji Matsumoto, Kouya Shiraishi, Yuki Shinno, Hidehito Horinouchi, Masayuki Shirasawa, Yasushi Goto, Koichi Goto, Sachiyo Mitani, Daisuke Takayanagi, Takashi Kohno, Yusuke Okuma, Hitoshi Ichikawa, Shingo Matsumoto, Shun-ichi Watanabe, Ken Masuda, Yukiko Shimoda
Publikováno v:
Journal of Thoracic Oncology. 16:2078-2090
Introduction Programmed death-ligand 1 (PD-L1) expression is not a completely reliable predictive marker of the efficacy of anti–programmed cell death protein-1 (PD-1)/PD-L1 therapy in patients with advanced NSCLC. Immune-related tumor microenviron
Autor:
Yasushi Goto, Sayaka Arakawa, Masayuki Shirasawa, Ryoko Higashiyama, Keisuke Baba, Ken Masuda, Yuki Shinno, Yuji Matsumoto, Yusuke Okuma, Tatsuya Yoshida, Hidehito Horinouchi, Noboru Yamamoto, Yuichiro Ohe
Publikováno v:
Japanese Journal of Clinical Oncology. 52:53-64
Introduction The accelerated development of lung cancer treatments has resulted in a single global study that is sufficient for a new agent and indication to be approved. Not all new treatments predominate globally, and differences in standards of ca